(VIANEWS) – Medpace Holdings (MEDP), Ford (F), Coca-Cola Consolidated (COKE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Medpace Holdings (MEDP)
17.8% sales growth and 66.57% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $8.52.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 35.62. Meaning, the purchaser of the share is investing $35.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.57%.
Volume
Today’s last reported volume for Medpace Holdings is 100041 which is 60.97% below its average volume of 256354.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Medpace Holdings’s EBITDA is 83.78.
Yearly Top and Bottom Value
Medpace Holdings’s stock is valued at $303.46 at 00:22 EST, below its 52-week high of $317.57 and way higher than its 52-week low of $167.00.
2. Ford (F)
16.2% sales growth and 14.15% return on equity
Ford Motor Company develops, delivers, and services a range of Ford trucks, commercial cars and vans, sport utility vehicles, and Lincoln luxury vehicles worldwide. It operates through Ford Blue, Ford Model e, and Ford Pro; Ford Next; and Ford Credit segments. The company sells Ford and Lincoln vehicles, service parts, and accessories through distributors and dealers, as well as through dealerships to commercial fleet customers, daily rental car companies, and governments. It also engages in vehicle-related financing and leasing activities to and through automotive dealers. In addition, the company provides retail installment sale contracts for new and used vehicles; and direct financing leases for new vehicles to retail and commercial customers, such as leasing companies, government entities, daily rental companies, and fleet customers. Further, it offers wholesale loans to dealers to finance the purchase of vehicle inventory; and loans to dealers to finance working capital and enhance dealership facilities, purchase dealership real estate, and other dealer vehicle programs. The company was incorporated in 1903 and is based in Dearborn, Michigan.
Earnings Per Share
As for profitability, Ford has a trailing twelve months EPS of $1.53.
PE Ratio
Ford has a trailing twelve months price to earnings ratio of 7.3. Meaning, the purchaser of the share is investing $7.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.15%.
Yearly Top and Bottom Value
Ford’s stock is valued at $11.18 at 00:22 EST, way below its 52-week high of $15.42 and way higher than its 52-week low of $9.63.
Sales Growth
Ford’s sales growth is negative 5.6% for the ongoing quarter and 16.2% for the next.
Previous days news about Ford(F)
- According to Zacks on Monday, 15 January, "U.S. legacy automaker Ford (F Quick QuoteF – Free Report) issued a recall for 140,000 units of the Focus and the EcoSport from model years 2016 to 2022 due to a defect in the engine oil pump drive belt tensioner arm.", "When the parts are available, the owners will be asked to visit a Ford or Lincoln dealership, where a technician will replace the oil pump drive belt tensioner assembly with an updated and durable part free of cost. "
3. Coca-Cola Consolidated (COKE)
11.7% sales growth and 35.46% return on equity
Coca-Cola Consolidated, Inc., together with its subsidiaries, manufactures, markets, and distributes nonalcoholic beverages primarily products of The Coca-Cola Company in the United States. The company offers sparkling beverages, such as sparling beverages; and still beverages, including energy products, as well as noncarbonated beverages comprising bottled water, ready to drink coffee and tea, enhanced water, juices, and sports drinks. It also sells its products to other Coca-Cola bottlers; and post-mix products that are dispensed through equipment, which mixes the fountain syrup with carbonated or still water enabling fountain retailers to sell finished products to consumers in cups or glasses. In addition, the company distributes products for various other beverage brands that include Dr Pepper and Monster Energy. It sells and distributes its products directly to grocery stores, mass merchandise stores, club stores, convenience stores, and drug stores; and restaurants, schools, amusement parks, and recreational facilities, as well as through vending machine outlets. The company was formerly known as Coca-Cola Bottling Co. Consolidated and changed its name to Coca-Cola Consolidated, Inc. in January 2019. Coca-Cola Consolidated, Inc. was incorporated in 1980 and is headquartered in Charlotte, North Carolina.
Earnings Per Share
As for profitability, Coca-Cola Consolidated has a trailing twelve months EPS of $48.01.
PE Ratio
Coca-Cola Consolidated has a trailing twelve months price to earnings ratio of 18.79. Meaning, the purchaser of the share is investing $18.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.46%.
4. BioMarin Pharmaceutical (BMRN)
10% sales growth and 3.11% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.77.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 124.53. Meaning, the purchaser of the share is investing $124.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.11%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BioMarin Pharmaceutical’s EBITDA is 232.97.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 195777 which is 88.85% below its average volume of 1756050.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $95.89 at 00:22 EST, way under its 52-week high of $117.77 and way above its 52-week low of $76.02.
5. FirstService Corporation (FSV)
8.4% sales growth and 14.17% return on equity
FirstService Corporation, together with its subsidiaries, provides residential property management and other essential property services to residential and commercial customers in the United States and Canada. The company operates in two segments, FirstService Residential and FirstService Brands. The FirstService Residential segment offers property management services for private residential communities, such as condominiums, co-operatives, homeowner associations, master-planned communities, active adult and lifestyle communities, and various other residential developments. This segment also provides a range of ancillary services, including on-site staffing for building engineering and maintenance, full-service swimming pool and amenity management, and security and concierge/front desk; and financial services comprising cash management, other banking transaction-related, and specialized property insurance brokerage. In addition, this segment offers energy management solutions and advisory services, and resale processing services. The FirstService Brands segment provides property services through 5 franchise networks; and company-owned locations, including 19 California Closets and 11 Paul Davis Restoration locations. It provides residential and commercial restoration, painting, and floor coverings design and installation services; custom-designed and installed closet, and home storage solutions; home inspection services; and fire protection and related services. This segment offers its services primarily under the Paul Davis Restoration, Interstate Restoration, FirstOnSite Restoration, Century Fire Protection, CertaPro Painters, California Closets, Pillar to Post Home Inspectors, and Floor Coverings International brand names. FirstService Corporation was founded in 1989 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, FirstService Corporation has a trailing twelve months EPS of $2.97.
PE Ratio
FirstService Corporation has a trailing twelve months price to earnings ratio of 54.58. Meaning, the purchaser of the share is investing $54.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.17%.
